ASCO to Launch its First Clinical Trial: TAPUR

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CHICAGO—The American Society of Clinical Oncology announced June 1 that it will move forward with its first-ever clinical trial, a study designed to offer patients with advanced cancer access to molecularly-targeted cancer drugs and to collect data on clinical outcomes to learn the best uses of these drugs outside of FDA-approved indications.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The landscape of cancer care in America faces critical challenges: geographic disparities in access, socioeconomic barriers to advanced treatments and the increasing complexity of precision medicine that outpaces individual providers’ ability to stay current. At City of Hope, we are addressing these systemic issues through a bold expansion that brings world-class cancer care and research closer to where patients live.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login